4.6 Article

The Contained Self-Reactive Peripheral T Cell Repertoire: Size, Diversity, and Cellular Composition

Journal

JOURNAL OF IMMUNOLOGY
Volume 195, Issue 5, Pages 2067-2079

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1500880

Keywords

-

Categories

Funding

  1. Helmholtz Association of German Research Centers [HZ-NG-505]
  2. Cooperation Program in Cancer Research of the German Cancer Research Center
  3. Israel's Ministry of Science, Technology and Space

Ask authors/readers for more resources

Individual self-reactive T cells have been discovered in both humans and mice. It is difficult to assess the entire contained self-reactive peripheral T cell repertoire in healthy individuals because regulatory T cells (Tregs) can render these cells anergic and, therefore, functionally indistinguishable. We addressed this issue by removing regulatory T cells, thereby allowing us to characterize the exposed self-reactive T cells. This resulted in activation of approximately 4% of both CD4(+) and CD8(+) T cells. Activation and division of these cells was not a bystander product of Ag-independent signals but required TCR stimulation. Analysis of TCR sequences showed that these responding cells were polyclonal and encompassed a broad range of structural TCR diversity. Adoptive transfer of naive and effector/memory T cell populations showed that even the naive T cell pool contained self-reactive T cell precursors. In addition, transfer of mature thymocytes showed that this response was an intrinsic T cell property rather than a peripheral adaptation. Finally, we found that the unexpectedly strong contribution of the naive CD5(low) T cell pool showed that the overall self-reactive response has not only a diverse polyclonal TCR repertoire, but also comprises a broad range of affinities for self.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biophysics

Prevention and treatment of relapse after stem cell transplantation by cellular therapies

Fred Falkenburg, Eliana Ruggiero, Chaira Bonini, David Porter, Jeff Miller, Floran Malard, Mohamad Mohty, Nicolaus Kroger, Hans Jochem Kolb

BONE MARROW TRANSPLANTATION (2019)

Article Rheumatology

CD4+Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade

Beatrice C. Cianciotti, Eliana Ruggiero, Corrado Campochiaro, Giacomo Oliveira, Zulma I. Magnani, Mattia Baldini, Matteo Doglio, Michela Tassara, Angelo A. Manfredi, Elena Baldissera, Fabio Ciceri, Nicoletta Cieri, Chiara Bonini

ARTHRITIS & RHEUMATOLOGY (2020)

Review Immunology

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Francesco Manfredi, Beatrice Claudia Cianciotti, Alessia Potenza, Elena Tassi, Maddalena Noviello, Andrea Biondi, Fabio Ciceri, Chiara Bonini, Eliana Ruggiero

FRONTIERS IN IMMUNOLOGY (2020)

Article Multidisciplinary Sciences

Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients

Maria Xydia, Raheleh Rahbari, Eliana Ruggiero, Iain Macaulay, Maxime Tarabichi, Robert Lohmayer, Stefan Wilkening, Tillmann Michels, Daniel Brown, Sebastiaan Vanuytven, Svetlana Mastitskaya, Sean Laidlaw, Niels Grabe, Maria Pritsch, Raffaele Fronza, Klaus Hexel, Steffen Schmitt, Michael Mueller-Steinhardt, Niels Halama, Christoph Domschke, Manfred Schmidt, Christof von Kalle, Florian Schuetz, Thierry Voet, Philipp Beckhove

Summary: Regulatory T cells in breast cancer do not show clonal relationship with their circulating counterpart, but share a common origin with intratumoral antigen-experienced conventional T cells.

NATURE COMMUNICATIONS (2021)

Article Immunology

Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells

Francesco Manfredi, Danilo Abbati, Beatrice Claudia Cianciotti, Lorena Stasi, Alessia Potenza, Eliana Ruggiero, Zulma Magnani, Erica Carnevale, Matteo Doglio, Maddalena Noviello, Elena Tassi, Chiara Balestrieri, Silvia Buonanno, Francesca Clemente, Claudia De Lalla, Maria Pia Protti, Anna Mondino, Giulia Casorati, Paolo Dellabona, Chiara Bonini

Summary: The article introduced a new tool called CytoChain for analyzing dynamic and complex flow cytometry samples to help researchers identify stem-like memory cells (T-SCM) suitable for adoptive T-cell therapy. By applying CytoChain, researchers successfully discovered a previously unidentified cell feature with superior expansion potential, providing support for new immunophenotypes in immunotherapy and patient immunomonitoring.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Article Cell Biology

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function

Eliana Ruggiero, Erica Carnevale, Aaron Prodeus, Zulma Irene Magnani, Barbara Camisa, Ivan Merelli, Claudia Politano, Lorena Stasi, Alessia Potenza, Beatrice Claudia Cianciotti, Francesco Manfredi, Mattia Di Bono, Luca Vago, Michela Tassara, Sara Mastaglio, Maurilio Ponzoni, Francesca Sanvito, Dai Liu, Ishina Balwani, Rossella Galli, Marco Genua, Renato Ostuni, Matteo Doglio, Daniel O'Connell, Ivy Dutta, Stephanie Ann Yazinski, Mark McKee, Mohamed Simo Arredouani, Birgit Schultes, Fabio Ciceri, Chiara Bonini

Summary: TCR-based therapy has the potential to induce durable clinical responses in cancer patients by targeting tumor antigens and promoting T cell survival. Isolated TCRs specific for WT1 and engineered T cells have shown effective killing of tumor cells, making them a promising candidate for immunotherapy.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Biology

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

Sara Feola, Jacopo Chiaro, Beatriz Martins, Salvatore Russo, Manlio Fusciello, Erkko Yloesmaeki, Chiara Bonini, Eliana Ruggiero, Firas Hamdan, Michaela Feodoroff, Gabriella Antignani, Tapani Viitala, Sari Pesonen, Mikaela Groenholm, Rui M. M. Branca, Janne Lehtioe, Vincenzo Cerullo, Ping-Chih Ho

Summary: We describe a streamlined pipeline for generating personalized cancer vaccines, starting from the isolation and selection of immunogenic peptide candidates expressed on tumor cells. The pipeline was validated in a mouse colon tumor model, confirming its feasibility and control of tumor lesions.

ELIFE (2022)

Article Medicine, Research & Experimental

Editing T cell repertoire by thymic epithelial cell-directed gene transfer abrogates risk of type 1 diabetes development

Fabio Russo, Eliana Ruggiero, Rosalia Curto, Laura Passeri, Francesca Sanvito, Ileana Bortolomai, Anna Villa, Silvia Gregori, Andrea Annoni

Summary: The study developed a gene transfer approach to modify the T cell repertoire in thymic epithelial cells, correcting the autoimmune response in type 1 diabetes. The strategy involved intrathymic injection of a lentiviral vector to achieve stable transgene expression in thymic epithelial cells, leading to successful correction of the disease in mice models.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Review Oncology

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models

Emmanuel Donnadieu, Maik Luu, Miriam Alb, Brigitte Anliker, Silvia Arcangeli, Chiara Bonini, Biagio De Angelis, Rashmi Choudhary, David Espie, Anne Galy, Cam Holland, Zoltan Ivics, Chahrazade Kantari-Mimoun, Marie Jose Kersten, Ulrike Koehl, Chantal Kuhn, Bruno Laugel, Franco Locatelli, Ibtissam Marchiq, Janet Markman, Marta Angiola Moresco, Emma Morris, Helene Negre, Concetta Quintarelli, Michael Rade, Kristin Reiche, Matthias Renner, Eliana Ruggiero, Carmen Sanges, Hans Stauss, Maria Themeli, Jan Van den Brulle, Michael Hudecek, Monica Casucci

Summary: The article introduces current preclinical models used to test the safety of engineered T cells, emphasizes the limitations of existing models, and proposes potential measures for improvement.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Review Oncology

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

Sonia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J. Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu, David Espie, Beatrice Greco, Richard Groen, Johannes B. Huppa, Chahrazade Kantari-Mimoun, Bruno Laugel, Mary Mantock, Janet L. Markman, Emma Morris, Concetta Quintarelli, Michael Rade, Kristin Reiche, Alba Rodriguez-Garcia, Juan Roberto Rodriguez-Madoz, Eliana Ruggiero, Maria Themeli, Michael Hudecek, Ibtissam Marchiq

Summary: Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a groundbreaking treatment in cancer medicine, and has the potential to be used in common solid tumors. However, in order to improve and accelerate the selection of lead T-cell products for clinical translation, it is necessary to assess preclinical models and develop new models with higher predictive value.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells

Michele Tomasi, Elena Caproni, Mattia Benedet, Ilaria Zanella, Sebastiano Giorgetta, Mattia Dalsass, Enrico Koenig, Assunta Gagliardi, Laura Fantappie, Alvise Berti, Silvia Tamburini, Lorenzo Croia, Gabriele Di Lascio, Erika Bellini, Silvia Valensin, Giada Licata, Guido Sebastiani, Francesco Dotta, Federica Armanini, Fabio Cumbo, Francesco Asnicar, Aitor Blanco-Miguez, Eliana Ruggiero, Nicola Segata, Guido Grandi, Alberto Grandi

Summary: A growing body of evidence supports the important role of the gut microbiome in cancer immunity, and it has been found that microbiome proteins can induce specific T cells, which can inhibit tumor growth. Furthermore, personalized mucosal cancer vaccines can be developed using engineered microbes and Outer Membrane Vesicles.

FRONTIERS IN ONCOLOGY (2022)

Article Immunology

Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B

Martina Musella, Andrea Guarracino, Nicoletta Manduca, Claudia Galassi, Eliana Ruggiero, Alessia Potenza, Ester Maccafeo, Gwenola Manic, Luca Mattiello, Sara Soliman Abdel Rehim, Michele Signore, Marco Pietrosanto, Manuela Helmer-Citterich, Matteo Pallocca, Maurizio Fanciulli, Tiziana Bruno, Francesca De Nicola, Giacomo Corleone, Anna Di Benedetto, Cristiana Ercolani, Edoardo Pescarmona, Laura Pizzuti, Francesco Guidi, Francesca Sperati, Sara Vitale, Daniele Macchia, Massimo Spada, Giovanna Schiavoni, Fabrizio Mattei, Adele De Ninno, Luca Businaro, Valeria Lucarini, Laura Bracci, Eleonora Arico, Giovanna Ziccheddu, Francesco Facchiano, Stefania Rossi, Massimo Sanchez, Alessandra Boe, Mauro Biffoni, Ruggero De Maria, Ilio Vitale, Antonella Sistigu

Summary: The study demonstrates that type I interferons can promote the formation of cancer stem cells by upregulating the chromatin remodeling factor KDM1B. Inhibition of KDM1B could potentially prevent stem cell expansion and increase the long-term benefit of therapy.

NATURE IMMUNOLOGY (2022)

Meeting Abstract Oncology

HARNESSING CD39 FOR THE TREATMENT OF COLORECTAL CANCER AND LIVER METASTASES BY ENGINEERED T CELLS

Alessia Potenza, Chiara Bonini, Chiara Balestrieri, Luca Albarello, Federica Pedica, Martina Spiga, Francesco Manfredi, Beatrice Cianciotti, Claudia De Lalla, Lorena Stasi, Elena Tassi, Silvia Bonfiglio, Giulia Scotti, Miriam Redegalli, Donatella Biancolini, Danilo Abbati, Fabio Simeoni, Dejan Lazarevic, Ugo Elmore, Guido Fiorentini, Giulia Di Lullo, Giulia Casorati, Paolo Dellabona, Claudio Doglioni, Giovanni Tonon, Riccardo Rosati, Luca Aldrighetti, Eliana Ruggiero

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Meeting Abstract Oncology

CRISPR/Cas9-mediated CD39 disruption can be combined with TCR editing in T cells to improve the adoptive T cell therapy of colorectal cancer

Alessia Potenza, Chiara Balestrieri, Luca Albarello, Federica Pedica, Lorena Stasi, Francesco Manfredi, Martina Spiga, Elena Tassi, Beatrice Claudia Cianciotti, Danilo Abbati, Ugo Elmore, Andrea Biondi, Luca Aldrighetti, Claudia De Lalla, Giulia Di Lullo, Paolo Dellabona, Eliana Ruggiero, Riccardo Rosati, Chiara Bonini

CANCER RESEARCH (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Editing T Cell Repertoire by Thymic Epithelial Cell-Directed Gene Transfer Abrogates

Fabio Russo, Eliana Ruggiero, Rosalia Curto, Laura Passeri, Francesca Sanvito, Ileana Bortolomai, Anna Villa, Silvia Gregori, Andrea Annoni

MOLECULAR THERAPY (2022)

No Data Available